SOLV · Solventum Corp · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| — | $8.31B | $8.33B | $8.25B | $8.2B | $8.13B | |
| — | $625M | $615M | $600M | $616M | $603M | |
| — | $4.55B | $4.45B | $4.59B | $4.69B | $4.7B | |
| — | — | 53.47% | 55.65% | 57.25% | 57.75% | |
| — | $724M | $739M | $775M | $758M | $767M | |
| — | $3.29B | $3.08B | $2.78B | $2.3B | $2.24B | |
| — | $333M | $312M | $349M | $365M | $373M | |
| — | $506M | $489M | $555M | $561M | $578M | |
| — | — | — | $62M | — | — | |
| — | $2.08B | $2.18B | $1.04B | $1.69B | $1.69B | |
| — | — | 26.2% | 12.55% | 20.64% | 20.82% | |
| — | $2.58B | $2.67B | $1.59B | $2.25B | $2.27B | |
| — | -$33M | -$39M | -$64M | -$25M | -$1M | |
| — | $1.7B | $1.71B | $605M | $1.67B | $1.69B | |
| — | $261M | $157M | $127M | $321M | $349M | |
| — | $1.43B | $1.56B | $479M | $1.35B | $1.34B | |
| — | — | 18.69% | 5.8% | 16.42% | 16.52% | |
| — | $1.4B | $1.99B | $291M | $1.47B | $1.05B | |
| USD/shares | — | $8.23 | $8.94 | $2.77 | $7.79 | $7.78 |
| USD/shares | $7.10 – $7.20* | $8.19 | $8.88G | $2.76G | $7.79 | $7.78 |
| shares | — | — | 174.1M | 173.2M | 172.7M | 172.7M |
| shares | — | — | 175.3M | 173.7M | 172.7M | 172.7M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported total debt history
| As of | Reported label | Amount | Source |
|---|---|---|---|
| 2025-12-31 | approximately $5 billion of outstanding indebtedness | USD 5,000,000,000 |
10-K filed 2026-02-27
In connection with the Spin-Off, Solventum completed certain financing transactions. As a result of such transactions and the subsequent repayment of debt with proceeds from the divestiture of the Purification and Filtration business, as of December 31, 2025, Solventum had approximately $5 billion of outstanding indebtedness. Depending on market or other economic conditions, Solventum could also incur additional indebtedness in the future. |
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current debt and lease obligations | 2026-06-30 | USD 506,000,000 | 10-Q filed 2026-08-05 |
| Finance lease liabilities | 2026-06-30 | USD 209,000,000 | 10-Q filed 2026-08-05 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent debt carrying amount | 2026-06-30 | USD 4,573,000,000 | 10-Q filed 2026-08-05 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 24 similar-size Medical Instruments & Supplies companies (of 51 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | $4,817,000,000 | $4,637,000,000 | $4,632,000,000 | $4,585,000,000 |
| Health Information Systems Segment | $1,360,000,000 | $1,306,000,000 | $1,285,000,000 | $1,227,000,000 |
| Dental Solutions Segment | $1,349,000,000 | $1,295,000,000 | $1,329,000,000 | $1,327,000,000 |
| Purification and Filtration Segment | $497,000,000 | $709,000,000 | $689,000,000 | $991,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $4,668,000,000 | $4,559,000,000 | $4,471,000,000 | $4,450,000,000 |
| Non Us | $3,657,000,000 | $3,695,000,000 | $3,726,000,000 | $3,680,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Product | $6,349,000,000 | $6,348,000,000 | $6,296,000,000 | $6,300,000,000 |
| Cost of Software and Rentals | $1,976,000,000 | $1,906,000,000 | $1,901,000,000 | $1,830,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | $810,000,000 | $887,000,000 | $1,107,000,000 | $1,061,000,000 |
| Health Information Systems Segment | $496,000,000 | $431,000,000 | $423,000,000 | $359,000,000 |
| Dental Solutions Segment | $346,000,000 | $350,000,000 | $442,000,000 | $437,000,000 |
| Purification and Filtration Segment | $96,000,000 | $74,000,000 | $111,000,000 | $177,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Med Surg Segment | 16.8% | 19.1% | 23.9% | 23.1% |
| Health Information Systems Segment | 36.5% | 33% | 32.9% | 29.3% |
| Dental Solutions Segment | 25.6% | 27% | 33.3% | 32.9% |
| Purification and Filtration Segment | 19.3% | 10.4% | 16.1% | 17.9% |